Sit Investment Associates Inc. Has $4.30 Million Holdings in Insulet Corporation $PODD

Key Points

• Sit Investment Associates Inc. has reduced its stake in Insulet Corporation (NASDAQ:PODD) by 26.3%, now owning 16,357 shares valued at approximately $4.3 million.
• A number of institutional investors, including Vanguard Group and Northern Trust Corp, have increased their positions in Insulet, with Vanguard owning 8.67 million shares valued at around $2.28 billion.
• Insulet reported a 32.9% year-over-year revenue growth for the last quarter, with earnings per share of $1.17, exceeding analyst expectations of $0.92.

Sit Investment Associates Inc. lessened its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 26.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,357 shares of the medical instruments supplier's stock after selling 5,850 shares during the quarter. Sit Investment Associates Inc.'s holdings in Insulet were worth $4,296,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. OLD National Bancorp IN lifted its holdings in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after acquiring an additional 55 shares during the period. Cooper Financial Group increased its stake in Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 58 shares during the last quarter. Syon Capital LLC raised its position in Insulet by 5.6% during the fourth quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after purchasing an additional 59 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after purchasing an additional 59 shares during the last quarter. Finally, HighTower Advisors LLC boosted its holdings in shares of Insulet by 2.1% in the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after purchasing an additional 60 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. The Goldman Sachs Group started coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 target price for the company. Raymond James Financial reissued an "outperform" rating and issued a $360.00 target price (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $330.71.

Insulet Trading Up 1.7%

NASDAQ PODD traded up $5.52 on Wednesday, hitting $333.00. The company's stock had a trading volume of 618,360 shares, compared to its average volume of 714,102. The company's 50-day moving average is $299.94 and its 200 day moving average is $285.21. The firm has a market cap of $23.44 billion, a PE ratio of 101.22, a PEG ratio of 2.74 and a beta of 1.35. Insulet Corporation has a 1-year low of $180.31 and a 1-year high of $333.41. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.